Milligan Sandra — SEC Form 4 filings
SEC reporting owner CIK 1859810. 12 Form 4 filings on record with FilingPulse; latest filed 2026-06-05.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-05-06 to 2026-06-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 26,050 shares, $50,016 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: purchase of 26,050 shares @ $1.92 ($50,016) in Gossamer Bio, Inc., filed 2025-08-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | Director | 4 | 1 leg · 26,050 sh · $50,016 | — | 3 |
| Aspira Women's Health Inc. (AWH) | Interim CEO | 5 | — | — | 8 |
| Spyre Therapeutics, Inc. (SYRE) | Director | 3 | — | — | 3 |
Form 4 filings — Milligan Sandra
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-05 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 8,026 (derivative) @ $0 | EDGAR |
| 2025-08-20 | 4 | Gossamer Bio, Inc. (GOSS) | Purchase (P): 26,050 @ $1.92 | EDGAR |
| 2025-06-26 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-01-29 | 4/A | Aspira Women's Health Inc. (AWH) | Option exercise (M): 20,000 @ $0 · Tax withholding (F): 6,356 @ $0.70 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Aspira Women's Health Inc. (AWH) | Option exercise (M): 20,000 @ $0 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-11-13 | 4 | Aspira Women's Health Inc. (AWH) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-10-28 | 4 | Aspira Women's Health Inc. (AWH) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 21,980 (derivative) @ $0 | EDGAR |
| 2024-05-06 | 4 | Aspira Women's Health Inc. (AWH) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1859810 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →